Our hypothesis is that the combined use of a CCR4 antagonist with antibiotic therapy may increase the survival rate after an initial insult and also guarantee long-term survival without immunosuppression, decreasing susceptibility to pulmonary infections, cancers, and cardiovascular diseases. This evidence concerns the gene CCR4 and cancer.